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Skin barrier dysfunction measured by transepidermal water
loss at 2 days and 2 months predates and predicts atopic
dermatitis at 1 year
Maeve Kelleher, MB,a Audrey Dunn-Galvin, PhD,a Jonathan O’B. Hourihane, DM,a,b Deirdre Murray, MD,a,b
Linda E. Campbell, BSc,c W. H. IrwinMcLean, DSc, FRS,c and Alan D. Irvine, MDb,d,e Cork and Dublin, Ireland, and Dundee,
United KingdomBackground: Loss-of-function mutations in the skin barrier
protein filaggrin (FLG) are a major risk for atopic dermatitis
(AD). The pathogenic sequence of disturbances in skin barrier
function before or during the early development of AD is not
fully understood. A more detailed understanding of these events
is needed to develop a clearer picture of disease pathogenesis.
A robust, noninvasive test to identify babies at high risk of AD
would be important in planning early intervention and/or
prevention studies.
Objectives: To ascertain whether a noninvasive measurement
of skin barrier function at day 2 after birth and at 2 months
predicts the development of AD at 1 year. Furthermore, to
determine whether increases in transepidermal water loss
(TEWL) predate the development of clinical AD.
Methods: A total of 1903 infants were enrolled in the Cork Babies
After Scope: Evaluating the Longitudinal Impact Using
Neurological and Nutritional Endpoints Birth Cohort study from
July 2009 toOctober 2011.Measurements of TEWLweremade at
birth (day 2) and at 2 and 6 months. The presence of AD was
ascertained at 6 and 12 months, and disease severity was assessed
by using the SCORing Atopic Dermatitis clinical tool at 6 months
and by using both the SCORing Atopic Dermatitis clinical tool
and Nottingham Severity Score at 12 months. A total of 1300
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930Results: At 6 months, 18.7% of the children had AD, and at 12
months, 15.53%. In a logistic regression model, day 2 upper
quartile TEWL measurement was significantly predictive of AD
at 12 months (area under the receiver operating characteristic
curve, 0.81; P <.05). Lowest quartile day 2 TEWLwas protective
against AD at 12 months. An upper quartile 2 month TEWL was
also strongly predictive of AD at 12 months (area under the
receiver operating characteristic curve, 0.84; P < .05). At both
ages, this effect was independent of parental atopy,FLG status, or
report of an itchy flexural rash at 2 months. Associations were
increased when parental atopy status or child FLG mutation
status was added into the linear regression model.
Conclusions: Impairment of skin barrier function at birth and at
2months precedes clinicalAD. In addition to providing important
mechanistic insights into disease pathogenesis, these findings have
implications for the optimal timing of interventions for the
prevention of AD. (J Allergy Clin Immunol 2015;135:930-5.)
Key words: Infant, skin barrier, TEWL, atopic dermatitis, filaggrin,
predictor, biomarker
Atopic diseases include atopic dermatitis (AD), food allergy,
allergic rhinitis, and asthma.1 The prevalence of these diseases
has increased in recent decades, causing considerable morbidity
in childhood.2-5 The putative ‘‘Atopic March’’ refers to the typical
sequence of clinical manifestation of atopic disease, usually
initiated by AD from early infancy.6,7
Parental atopy is an independent risk factor for the development
of atopic disease.8 The geneticmechanismsand inheritance pattern
of atopic diseases are not fully elucidated, but recent candidate
gene studies and genomewide association studies have yielded
some insights.9 The most widely replicated and most significant
gene to influence AD is filaggrin (FLG).10 Filaggrin is a
filament-binding protein in the stratum corneum.11 FLG loss-of-
function mutations occur in 10% of Europeans, imparting an
increased risk of AD, food allergy, and asthma.12,13 The overall in-
crease in the risk ofAD conferred by a singleFLG loss-of-function
mutation is approximately 3.3,14 with a significant additional and
independent effect conferred by intragenic copy number variations
in FLG.15 Importantly, FLG mutations increase the risk of
developing asthma only in the presence of AD.13
The stratum corneum contributes greatly to skin barrier
function. Transepidermal water loss (TEWL) is a noninvasive
in vivo measurement of water loss across the stratum corneum.16
It is raised in subjects with AD.13 This is seen at both lesional and
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and anothernonlesional skin sites.17,18 Recent studies of high-risk atopic
individuals showed that a raised TEWL may precede the clinical
manifestation of AD in those at high risk of atopy.19 A defect in
skin barrier function may facilitate allergen entry and immune
priming.20 Further evidence for this theory has been gained
from murine studies in which systemic allergic reactions to
peanut can be induced by epicutaneous sensitization across a
disrupted stratum corneum.21 Such a defect has been proposed
as a risk factor and a route of sensitization for the development
of peanut allergy.22 With regard to aeroallergens, in a
cross-sectional study of children, an increased TEWL is
associated with increased sensitization to aeroallergens.23
Currently, no primary preventative therapies have been
established for AD. Given the role of filaggrin, pilot studies
have focused on therapies or interventions that may enhance the
infant skin barrier.24 Very recently 2 studies have shown that
application of moisturizer in the neonatal period holds promise
for the prevention of AD.25,26 To date though, apart from family
history, there is no way of accurately identifying which children
may be at the greatest risk of AD and who might therefore benefit
most from intervention. In this study, we sought to determine
whether a rapid and noninvasive test such as TEWL, measured
at day 2 and month 2, could predict the development of AD at
12 months. Given the well-established role of FLG mutations,
we included genetic status in our predictive model and we also
included parental atopy.METHODS
Study subjects
The Cork Babies After Scope: Evaluating the Longitudinal Impact Using
Neurological and Nutritional Endpoints (BASELINE) Birth Cohort study is
the first birth cohort study in Ireland.27 It was developed as the pediatric follow
on from the Cork Centre for the Screening for Pregnancy Endpoints (SCOPE)
study, a multicenter international study evaluating diseases of pregnancy in
primigravidous women.28 The Cork BASELINE Birth Cohort study recruited
from August 2009 through to October 2011. Infants recruited from July 2009
had skin barrier assessment at birth and throughout early life; these 1903
infants are included in this study.
A total of 1303 infants were recruited antenatally (stream1). These women
were subject to the inclusion criteria of the SCOPE study, namely, first-time,
low-riskmotherswith singleton pregnancies delivered at or near term. Consent
for recruitment was sought at 20 weeks of gestation and confirmed at birth of
the live baby. Cord blood samples were taken at birth and stored for future use.
A second recruitment stream began in July 2010 that recruited mothers and
babies on the postnatal ward (stream2). A total of 600 infants were recruited
postnatally. These mothers were enrolled independently of the SCOPE study.The sole inclusion criterion in stream 2 was a healthy term infant on the
postnatal ward. Stream1 and stream2 infantswere assessed and followed up in
an identical fashion at birth and thereafter clinic visits at 2, 6, and 12 months.
All infants had assessment at birth, 2 months, 6 months, and 12 months
involving parental questionnaires and physical assessment. Parental question-
naires at 2, 6, and 12 months contained specific screening questions for AD.
Experienced health care personnel diagnosed AD at 6 and 12 months in
accordance with the UK Working Party diagnostic criteria.29-31 If AD was
present, severity was assessed at these timepoints using the SCORing Atopic
Dermatitis (SCORAD) clinical tool.32,33 At 12 months, the Nottingham
Severity Score was also recorded to assess the severity of AD.34
TEWL measurements
TEWLmeasurementswere carried out using awidely validated open chamber
system(TewameterTM300;Courage1KhazakaElectronic,Cologne,Germany).
For newborns, TEWL was taken in the Cork University Maternity Hospital. The
subject’s arm was acclimated before measurement by exposing the arm in a
nonenvironmentally controlled room for 10 minutes. This was typically done in
the cot beside themother’s bedwhile an interviewwith themother or parents was
carried out. The infant was then brought to a windowless room in which both
temperature and humidity were maintained constant by an air conditioning
system. Temperature was set between 208C and 258C. Humidity was monitored
by a manometer in the room and was maintained between 30% and 45%. TEWL
was taken on the lower volar surface of the forearm by applying a probe to the
exposed volar skin for approximately 15 seconds until the measurement was
recorded.Three readingswere taken, and themeanof the3 readingswas recorded.
For TEWL readings at other timepoints, the same procedure was carried out at 2
months and 6 months in an environmentally controlled room in the Health
Research Board Discovery Centre, the clinical research facility for children at
CorkUniversity Hospital. The parents were advised not to apply emollients to the
infant’s skin for 12 hours before the reading was taken.
Statistical analysis
Aseries of logistic regression (LR)modelswas used to estimate the factors at
(1) 2 days and (2) 2months that influence the diagnosis ofADat 12months. The
dependent variable that measures diagnosis at 12 months is AD ‘‘Yes’’ and is
equal to 1, with AD ‘‘No’’5 0. To examine the influence of each variable, with
and without the presence of other significant predictors, we carried out both
univariable and multivariable analyses.With regard to the latter, 3 models were
produced. Model 1 included parental atopy, FLGmutation status, and presence
of an itchy rash at 2months as independent variables.Model 2 included parental
atopy andTEWL test reading scores at 25th, 50th, and 75th percentiles (7.0, 9.4,
and 12.3, respectively) as independent variables, but did not include FLG mu-
tation status. This was done to determine the unique influence of TEWL,
without the contribution of FLG mutations. Model 3 included all independent
variables: parental atopy, TEWL test reading scores, and FLGmutation status.
All models controlled for the variables ‘‘use of emollient before test reading,’’
‘‘presence of an itchy rash,’’ ‘‘infant sex,’’ and ‘‘infant birthweight.’’ Receiver
operating characteristic (ROC) curve output, which plots the true positives
(sensitivity) vs false positives (12 specificity), was then evaluated to compare
the ability of the 3 models to produce a prognosis with high accuracy. Our
rationale for variable selection was to include those predictors necessary for
face validity but only if they were significant at a .05 level in the univariable
analysis or if they altered the coefficient of the main variable by more than
10% in cases in which the main association was significant.35,36
RESULTS
A total of 1903 infants were enrolled onto the study. The
demographic details of the population studied are presented in
Table I.Filaggrin mutation typing
Stream 1 infants had cord blood samples taken at birth. Infants
without cord blood samples had Oragene saliva samples taken.
TABLE I. Baseline demographic characteristics
Characteristic Value
Total enrolled 1903
Sex: male/female (%) 50.4/49.6
Birthweight (g), mean 6 SD 3489 6 512
Gestation (d), mean 6 SD 279.33 6 10.77





rate (%) Total (%)
R501X 4.0 (52 of 1300) 0.23 (3 of 1300) 4.23 (55 of 1300)
2282Del4 3.62 (47 of 1300) 0 3.6 (47 of 1300)
S3247X 1.54 (20 of 1300) 0.08 (1 of 1300) 1.62 (21 of 1300)
R2447X 1 (13 of 1300) 0 1 (13 of 1300)
FLG mutation
(total)
10.15 (132 of 1300) 0.31 (4 of 1300) 10.46 (136 of 1300)















25 5.0 45 7.0 43
50 7.0 27 9.4 21
75 9.0 28 12.3 36




P valueFLG wild-type FLG mutation
N 1164 136
Birth 7.3 6 3.38 7.33 6 3.62 .91
2 mo 10.7 6 7.7 12.6 6 10.1 .04
6 mo 10.42 6 7.1 12.25 6 6.53 .007
D Birth to 2 mo 3.32 6 8.1 5.44 6 10.66 .046
D Birth to 6 mo 2.93 6 7.55 4.62 6 7.11 .03
D 2 to 6 mo 0.35 6 10.11 0.75 6 9.95 .685
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samples taken. FLG genotyping was carried out in 1300 infants
with available DNA. The cumulative FLG mutation rate was
10.46% (136 of 1300). Four infants were homozygous for FLG
mutation, with the remainder heterozygous for FLG mutation
(Table II).TEWL through early infancy
TEWL was taken in the early newborn period in 1691 of 1903
(88.86%) infants of the cohort. The mean TEWL for newborns
was 7.326 3.33 gwater/m
2/h. Using univariable analysis, we found
that there was no significant association between TEWL
measurements at birth and sex, gestation, or postnatal age at
measurement or recruitment stream 1 or 2 (data not shown).
A total of 1614 of 1638 (98.5%) infants who attended the
2-month appointment had TEWL measured (98.5%). Mean
2-month TEWL was 10.97 6 7.98 gwater/m
2/h. A total of 1516
of 1537 (98.6%) infants who attended the 6-month appointment
had TEWL measured. Mean 6-month TEWL was 10.71 6 7.10
gwater/m
2/h. TEWL measurements by quartiles are presented in
Table III.Clinical diagnosis of AD
AD was screened for at 6- and 12-month appointments.
This diagnosis of AD was made according to the UK Working
Party diagnostic criteria. At 6 months, 18.7% (299 of 1597) of
the infants screened were diagnosed with AD. A total of 287
had a SCORAD completed, with a mean SCORAD score of
21.546 16.29 (range, 0-88). At 12months, 15.53% (232 of 1494)
of the infants screened were diagnosed with AD. The
mean SCORAD score at 12 months in affected children was
18.56 6 14.92 (range, 0-77).LR analysis: Factors influencing the development of
AD at 1 year
Our primary outcome was the presence of AD at 1 year. We
developed amodel that explored the relative contributions ofFLG
mutation status, parental atopy, presence of an itchy rash at 2months, TEWL at day 2 and month 2, and DTEWL (day 2 to
month 2 and day 2 to month 6) on AD at 1 year (Table IV).
FLG mutation status was not associated with an elevated
TEWL at birth. However, it was associated with an elevated
TEWL at 2 and 6 months and with elevated DTEWL day 2 to 2
months and DTEWL day 2 to 6 months. Notably, FLG mutation
carriers did not have elevated DTEWL 2 months to 6 months,
implying that the major changes in skin barrier function in those
who develop AD by 12months start in the first 2 months of life. In
our univariable modeling, the odds ratio (OR) for AD at 12
months conferred by both parents being atopic was 2.5 compared
with an OR of 3.1 for an upper quartile TEWL at 2 months (see
Table E1 in this article’s Online Repository at www.jacionline.
org). LR models were then used to examine the factors at birth
and at 2 months that influence a diagnosis of AD at 12 months.
We used 3 separate models to explore the relative contribution
of parental atopy, FLG mutation status, and TEWL (at day 2
and at 2 months) toward the development of AD at 12 months.
All models controlled for the variables use of emollient before
test reading, presence of an itchy rash, infant sex, and infant
birthweight. These covariates were not significant in any of the
3 multivariable models.LR modeling of AD risk at 12 months including day
2 TEWL
The LR model incorporating day 2 TEWL is summarized in
Table V. In our first model, we included parental atopy and FLG
mutation status as independent variables and excluded day 2
TEWL. Parental atopy and FLG mutation status significantly
increase the likelihood of a positive diagnosis of AD at 12 months
by 13.7 and 8.6 times, respectively, compared with infants
TABLE V. LR model for factors at birth influencing AD at 12 months
Predictor variable at birth
OR; CI (P value)
Model 1 Model 2 Model 3
Parental atopy
None — — —
One (yes) 10.2; 1.4-11.8 (.05) 1.7; 0.5-4.8 (.2) 11.5; 0.3-5.6 (.1)
Both (yes) 13.7; 1.0-25.4 (.05) 9.0; 4.4-20.4 (.001) 13.4; 1.2-14.0 (.1)
FLG loss-of-function mutation
No — — —
Yes 8.6; 1.1-24.7 (.02) — 10.2; 1.2-18.5 (.3)
TEWL birth percentiles
25th (5.0 gwater/m
2/h) — — —
50th (7.0 gwater/m
2/h) — 3.2; 0.9-15.0 (.07) 1.9; 0.3-17.7 (.9)
75th (9.0 gwater/m
2/h) — 7.1; 1.8-12.9 (.001) 6.9; 0.6-34.3 (.1)
Adjusted for
Use of emollient (yes) 0.8; 0.3-2.5 (.8) 0.8; 0.3-2.0 (.6) 0.7; 0.2-2.2 (.7)
Sex (male) 0.9; 0.3-4.0 (.7) 0.8; 0.3-1.9 (.6) 0.9; 0.3-2.5 (.8)
Birthweight 1.0; 0.9-1.1 (.5) 1.0; 0.9-1.1 (.5) 1.0; 0.9-1.1 (.5)
Visible itchy rash 1.3; 0.3-5.9 (.7) 2.1; 0.7-6.3 (.2) 0.7; 0.2-3.2 (.6)
Baseline 1 vs 2 2.8; 0.7-11.5 (.2) 2.3; 0.6-8.1 (.2) 3.1; 0.7-13.2 (.2)
Model x2 statistic for overall model fit 18.5 (.05) 14.7 (.04) 16.3 (.05)
AUC 0.8; 0.7-0.9 (.01) 0.8; 0.7-0.9 (.01) 0.83; 0.7-0.9 (.01)
Controlling for ‘‘use of emollient before test reading,’’ ‘‘visible itchy rash at 2 months,’’ ‘‘infant sex,’’ and ‘‘infant birthweight.’’
TABLE VI. LR model for factors at 2 months influencing AD at 12 months
Predictor variable at birth
OR; CI (P value)
Model 1 Model 2 Model 3
Parental atopy
None — — —
One (yes) 1.4; 0.4-2.7 (.6) 1.7; 0.5-4.8 (.2) 1.5; 0.3-5.6 (.1)
Both (yes) 2.7; 1.3-4.1 (.01) 9.0; 4.4-20.4 (.001) 6.5; 1.2-14.0 (.01)
FLG loss-of-function mutation
No — — —
Yes 3.1; 2.0-4.9 (.02) — 2.9; 0.4-19.5 (.28)
TEWL 2-mo percentiles
25th (7.0 gwater/m
2/h) — — —
50th (9.4 gwater/m
2/h) — 1.1; 0.3-3.8 (.9) 1.5; 0.3-4.1 (.9)
75th (12.3 gwater/m
2/h) — 5.6; 1.8-12.9 (.001) 7.9; 1.7-25.0 (.01)
Adjusted for
Use of emollient (yes) 1.1; 0.3-3.5 (.8) 1.2; 0.4-3.1 (.7) 0.5; 0.5-6.1 (.3)
Sex (male) 0.9; 0.3-2.4 (.7) 0.9; 0.3-2.1 (.6) 0.9; 0.8-1.1 (.8)
Birthweight 1.0; 0.9-1.0 (.3) 1.0; 0.9-1.0 (.4) 0.9; 0.8-1.0 (.3)
Visible itchy rash 1.3; 2.1-5.3 (.7) 0.7; 0.2-2.4 (.6) 1.6; 0.3-8.2 (.6)
Baseline 1 vs 2 2.8; 0.7-11.5 (.2) 1.8; 0.5-6.5 (.4) 2.6; 0.5-11.6 (.2)
Model x2 statistic for overall model fit 64.0 (.04) 34.2 (.005) 26.3 (.01)
AUC 0.66 (.01) 0.82 (.01) 0.84 (.01)
Controlling for ‘‘use of emollient before test reading,’’ ‘‘visible itchy rash at 2 months,’’ ‘‘infant sex,’’ and ‘‘infant birthweight.’’
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which plots the true positives (sensitivity) vs false positives
(12specificity), is 0.8 for this model. Our second model includes
day 2 TEWL test reading scores at 25th, 50th, and 75th percentiles
as independent variables. We did not include FLGmutation status
in this second model. The area under the ROC curve (AUC)
remains at 0.8 for this model. Infants with a TEWL reading of
9.0 or above are 7.1 times more likely to be diagnosed with AD
at 1 year than are infants with a reading below this point,
controlling for all other variables in the model. This suggests
that day 2 TEWL can be used as a sole indicator of likelihood
of AD at 12 months. Our third model includes all independent
variables, including both TEWL and FLG status.LR modeling of AD risk at 12 months including
TEWL at 2 months
We repeated the LR approach for month 2 TEWL values,
summarized in Table VI. Again, we used 3 models. In the first
model, we included parental atopy and FLG mutation status as
independent variables but did not include TEWL. Parental atopy
andFLGmutation carriage significantly increase the likelihood of
a positive AD diagnosis at 12 months by 2.7 and 3.0 times,
respectively, compared with infants without an FLG mutation
and without an atopic parent. The ROC is 0.66 for this model.
In the second model, we included the month 2 TEWL test
reading scores at 25th, 50th, and 75th percentiles (7.0, 9.4, and
12.3 gwater/m
2/h, respectively) as independent variables. We did
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explained above. The AUC improved from 0.66 to 0.82 in this
model. Infants with a TEWL reading of 12.3 or above were 5.6
times more likely to be diagnosed with AD at 12 months than
were infants with a reading below this point, controlling for all
other variables in the model. Model 3 included all independent
variables. In a pattern similar to that found at 2 days, the AUC
improved slightly to 0.84, although here again it is important to
note that model 2 demonstrates that FLG status need not be
measured to produce a prognosis with high accuracy.Wemodeled
these in a traditional stepwise LR analysis. The significant finding
was that after controlling for all other possible influencing factors,
month 2 TEWL was the strongest independent predictor of AD at
12 months.DISCUSSION
This study involves a large, unselected birth cohort study and is
the first study of this scale to assess skin barrier function in the
newborn period and early infancy.We have shown that changes in
skin barrier predate clinical AD with a signal for barrier
impairment detected in asymptomatic infants at day 2 and more
markedly at 2 months. In our univariable modeling, the OR for
AD at 12 months conferred by both parents being atopic was 2.5
compared with an OR of 3.1 for an upper quartile TEWL at 2
months (see Table E1), showing the additional value of an TEWL
reading at this stage. These changes are seen in both high-risk and
low-risk infants and, crucially, are independent of FLG status.
Although in our multivariable analysis the AUC improves slightly
to 0.83 when all available variables are included, importantly our
second model (which excludes FLG genotyping) demonstrates
that FLG status need not be measured to produce an accurate
12-month AD prognosis for babies with upper quartile day 2
TEWL readings.
Some children will develop AD before 6 months. In our study,
we did not formally diagnose AD at 2 months but all parents were
asked about the presence of itchy rash on face or skin folds. These
infants were designated as ‘‘itchy rash,’’ seen in 8% of all cases at
2 months. There are no widely recognized diagnostic criteria for
AD at this age; however, we controlled for an itchy red rash at the
2-month visit in our model. AD was screened for in all
participants at 6 and 12 months and formally diagnosed using
the UK Working Party Criteria. When compared with other
studies in the field, our study shows the earliest timepoint for a
signal for impaired TEWL in asymptomatic infants: at day 2.
A further, stronger signal is seen at 2 months.
Previous studies, of smaller scale have shown a relationship
betweenFLGmutation status and TEWL.19 However, our study is
much larger, by several orders of magnitude, and is not selected
for high risk of atopy. In our study, 30% of FLGmutation carriers
developed AD by age 12 months and 70% did not, consistent with
large previous studies. At birth, there was no difference in mean
TEWL reading betweenFLGmutation andFLGwild-type groups
(7.336 3.62 gwater/m
2/h vs 7.36 3.38 gwater/m
2/h). However, by
2 months, FLG mutation carrying infants have a significantly
higher mean TEWL than do FLG wild-type infants. This change
persisted at 6 months.
Selecting out children in the upper quartile regardless of FLG
status allows for a noninvasive, discriminating, and targeted
means of prediction of AD in the first days of life, allowing for
possible preventive measures to be put in place. Conversely,selecting out infants in the lower quartile of TEWL, which has
a protective effect in relation to AD at 12 months, could be an
important piece of positive information for their families and
would reduce the ‘‘number needed to treat’’ in an intervention
study of potential protective interventions. Detection of an
increased TEWL as early as day 2 or at 2 months, before
developing clinical features of AD, is a novel and unique finding
in a general pediatric population. Accurate identification of
individuals at high risk for AD, using family history in
combination with a noninvasive measurement, with the optional
addition of FLG mutation status has great potential for
intervention studies. Stratified interventions could be made on
the basis of these 2 or 3 variables. Pilot studies for the primary
prevention of AD by use of liberal emollients have shown the
potential of this approach.24 We believe that the novel findings
in this study will facilitate and inform stratification of future
intervention studies.
A lowest quartile TEWL at birth is protective against AD.
A highest quartile TEWL at 2 days and at 2 months is strongly
associated with increased prevalence of AD at 12 months. These
changes predate the development of clinically apparent AD. The
mechanistic implications of these observations are that
abnormalities in the skin barrier predate symptomatic or
clinically detectable AD. These changes occur very early in the
postnatal environment after transition from the intrauterine
aqueous environment to the xerotic postnatal environment. It is
notable that this effect is not dependent on FLG loss-of-function
mutations but is enhanced by and is interactive with these genetic
factors and presumably with environmental influences
encountered postnatally. TEWL measurement in early life is
therefore an effective tool to detect infants at risk of AD,
especially when combined in a model with parental history of
atopy and/or FLG mutation status. The obvious next step would
be to assess whether intervention studies between birth and age
2 months in those with raised TEWL at birth would be effective
in maintaining the skin barrier and reducing the incidence of AD.
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Clinical implications: A signal for the development of AD is seen
at 2 days and at 2 months in asymptomatic infants. Interven-
tions to potentially prevent AD could be targeted toward such
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TABLE E1. Univariate table





2/h) 1.9 1.27-2.86 .002
75th (9.0 gwater/m





2/h) 1.4 0.95-1.95 .9
75th (12.3 gwater/m
2/h) 3.1 2.21-4.22 .0001
Parental atopy
None —
One (yes) 1.4 1.03-2.01 .03
Both (yes) 2.5 1.67-3.66 .0001
Visible rash at 2 mo (yes) 2.7 1.88-4.1 .001
FLG loss-of-function mutation (yes) 2.9 1.94-4.45 .0001
Use of emollient 1.1 0.6-2.4 .1
Baseline 1 vs 2 1.1 0.9-1.53 .3
Birthweight 1.01 1.0-1.2 .4
Sex 0.91 0.7-1.2 .4
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